COMPANY:

Lunit

"Lunit...today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2023. Lunit will deliver five poster presentations featuring its AI-biomarker platform at the annual meeting to be held in Orlando, Florida, on April 14-19."

"Lunit said it has completed validation of Lunit Scope PD-L1, its artificial intelligence pathology analysis solution, in Clinical Laboratory Improvement Amendments (CLIA)'s laboratory-developed test (LDT)...The company conducted the test at Guardant Health's CLIA Lab."

"Guardant Health, Inc...announced today the introduction of Guardant Galaxy^TM, a suite of advanced analytical technologies developed internally and through outside partnerships to enhance the performance and clinical utility of Guardant Health’s portfolio of cancer tests and to power the next generation of biomarker and drug discovery....The AI-powered scoring algorithm for the enhanced Guardant360 TissueNext PD-L1 test, which is now commercially available, improved detection of the cancer biomarker by more than 20 percent compared to manual pathologist interpretation in the most challenging non-small cell lung cancer (NSCLC) cases....Guardant Health also plans to expand the Guardant Galaxy technology suite over time to include other technology partnerships that will support additional segments of its cancer diagnostics portfolio."

"Lunit...announced that it will deliver two poster presentations at the upcoming 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held in San Francisco, CA, and online from Jan. 19 - 21....Findings showed progression-free survival (PFS) of the nivolumab or nivolumab plus ipilimumab (Niv+/-Ipi) regimen to be significantly longer in patients with high inflamed scores—the proportion of area with a high intra-tumoral TIL infiltration. Thus, results showed that the inflamed score, as evaluated by Lunit SCOPE IO, can be used as a biomarker to predict outcomes of Niv+/-Ipi treatment. Lunit will also present findings from a study assessing the clinical significance of Lunit SCOPE IO for the prediction of prognosis in stage II-III colon cancer patients treated with surgery and adjuvant chemotherapy."

"Lunit...announced that it will present three abstracts at the upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, to be held in Boston, MA, and virtually from Nov. 8 – 12...Lunit’s presentations at SITC 2022 will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development."

"Lunit will also present clinical findings that demonstrate the accuracy of Lunit SCOPE PD-L1 CPS. After classifying PD-L1 Combined Positive Score (CPS) levels in 543 urothelial carcinoma (UC) cases, the AI-powered CPS analyzer showed an equivalent level of accuracy to that of pathologists....Another study from Lunit reveals the capability of the AI-powered TIL and PD-L1 CPS analysis solution to be utilized as a predictive biomarker for immune checkpoint inhibitor (ICI) response in neuroendocrine neoplasms (NEN)....The last study shows that Lunit SCOPE can discover novel targets for antibody-drug conjugates (ADC) by precisely analyzing linked NGS and IHC data in tumors, highlighting the potential of multimodal analysis linking molecular and visual methods."

"A new phase II clinical trial validated the efficacy of Lunit’s AI biomarker, Lunit SCOPE IO, in predicting outcomes of immunotherapy in patients with nasopharyngeal carcinoma. The study has been published in Clinical Cancer Research...'This study shows that, by applying Lunit SCOPE IO to a clinical trial, it is possible to find a target group that responds better to treatment'..."

"Lunit...announced that it has signed a contract with FujiFilm Thailand and Microsoft to supply AI cancer screening products to Bumrungrad International Hospital, located in Bangkok, Thailand. Under the agreement, Lunit INSIGHT CXR, a CE-marked chest x-ray analysis AI software, and Lunit INSIGHT MMG, an FDA-cleared AI solution for detecting breast cancer in early stages, are deployed in Bumrungrad hospital."

"New findings demonstrate the clinical efficacy of AI-powered tissue analysis as a guide in cancer treatment, according to medical AI provider Lunit. The findings will be presented at the 2022 ASCO Annual Meeting, to be held from June 3 to 7...One of the poster presentations by Lunit elaborates on the validation of the Inflamed Immune Phenotype (IIP) as a practical biomarker to guide immune checkpoint inhibitor (ICI) treatment. The IIP is assessed by Lunit SCOPE IO, Lunit’s AI-powered immune phenotype analyzer, from H&E slide images...Lunit will also deliver a presentation on Lunit SCOPE PD-L1 TPS, the company’s AI-powered PD-L1 tumor proportion score (TPS) analyzer."

"A recent study revealed that with the assistance of AI, multiple pathologists showed improved consensus in analyzing PD-L1 tumor proportion scores, finding more patients eligible for immunotherapy. The study has been published on May 14 in the European Journal of Cancer (EJC)...Findings from the study demonstrate the clinical efficacy of Lunit SCOPE PD-L1, the company’s AI-powered programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) analyzer, which recently received the CE mark for commercial use in the European market."

"Lunit...announced it has received the CE-IVDD Mark for ‘Lunit SCOPE PD-L1 TPS’, an AI-based PD-L1 tumor proportion score (TPS) analyzer...Lunit SCOPE PD-L1 is an AI solution that performs PD-L1 TPS classification that enhances objective and accurate analysis compared to traditional method...Lunit is working on launching Lunit SCOPE PD-L1 in Europe within the second half of 2022, paving the way for deployment and use in European pathology practices."

"Lunit today announced the presentation of 11 abstracts featuring its AI-biomarker platform at the 2022 ASCO Annual Meeting from June 3 to 7....Findings from the study validate the effectiveness of Lunit SCOPE IO—Lunit's AI biomarker—in predicting clinical outcomes of immunotherapy across more than 16 different cancer types....In addition, Lunit will also present clinical findings that demonstrate the accuracy of its AI imaging solution in detecting high-risk breast cancer patients."